Role of adjuvant imatinib dose in radically resected GIST harboring KIT exon 9 mutations.

11533Background: Gastrointestinal stromal tumors (GIST) with a driver mutation in KIT exon 9 (Ex9) represent about 10% of all newly diagnosed cases. In the metastatic setting, Ex9-mutated GIST pati...